Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Reinforcement Schedules01:24

Reinforcement Schedules

479
Positive reinforcement is a powerful method for teaching new behaviors to both animals and humans. B.F. Skinner demonstrated this with his experiments using rats in a Skinner box. When a rat pressed a lever, it received a food pellet. This immediate reward encouraged the rat to repeat the behavior. This method, where a reward follows every instance of the behavior, is known as continuous reinforcement. It is highly effective for establishing new behaviors quickly.
Once a behavior is learned,...
479
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

220
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
220
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

217
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
217
Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point.

BMC medical research methodology·2025
Same author

A robust Bayesian dose optimization design with backfill and randomization for phase I/II clinical trials.

Statistical methods in medical research·2025
Same author

A model-free phase I/II dose optimization design for immunotherapy trials.

Statistical methods in medical research·2025
Same author

A Phase I Dose-Finding Design Incorporating Intra-Patient Dose Escalation.

Pharmaceutical statistics·2024
Same author

A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials.

Pharmaceutical statistics·2024
Same author

Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.

Clinical trials (London, England)·2024

Video Experimental Relacionado

Updated: Jan 24, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

Diseño de optimización de dosis basado en biomarcadores para ensayos de inmunoterapia

Yingjie Qiu1,2, Yan Han3, Beibei Guo4

  • 1Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Statistics in medicine
|January 23, 2026
PubMed
Resumen

La optimización de la dosis y el esquema del fármaco de inmunoterapia es crucial. Este estudio propone una estrategia a medida que utiliza la respuesta inmune, la eficacia y los datos de toxicidad para subgrupos de biomarcadores, mejorando la toma de decisiones en ensayos clínicos.

Palabras clave:
diseño adaptativo bayesianobiomarcadorinmunoterapiarégimen de tratamiento óptimoensayo de fase I/IIcompensación riesgo-beneficiosubgrupos

Más Videos Relacionados

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.3K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

Videos de Experimentos Relacionados

Last Updated: Jan 24, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.3K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

Área de la Ciencia:

  • Inmunoterapia; Diseño de Ensayos Clínicos; Bioestadística

Sus antecedentes:

  • La dosis y el esquema del fármaco impactan significativamente la eficacia de la inmunoterapia al modular las respuestas inmunes.
  • La integración de medidas de respuesta inmune en los ensayos clínicos ayuda a la toma de decisiones debido a su vínculo con la eficacia y la toxicidad.
  • Los datos de biomarcadores pueden identificar subgrupos de pacientes con mayor eficacia del tratamiento.

Objetivo del estudio:

  • Desarrollar una estrategia de optimización de dosis-esquema para ensayos clínicos de inmunoterapia.
  • Adaptar la optimización del tratamiento a subgrupos de pacientes definidos por biomarcadores.
  • Aprovechar los datos de respuesta inmune, toxicidad y eficacia para mejorar la toma de decisiones.

Principales métodos:

  • Se desarrolló un marco de modelado conjunto para evaluar simultáneamente la respuesta inmune, la toxicidad y la eficacia.
  • Se obtuvieron funciones de utilidad para capturar las compensaciones riesgo-beneficio específicas del paciente.
  • Se emplearon modelos parsimoniosos pero flexibles para manejar tamaños de muestra pequeños en ensayos de fase temprana.

Principales resultados:

  • El marco de modelado conjunto propuesto permite compartir información entre diferentes tipos de resultados y subgrupos de pacientes.
  • Los estudios de simulación demostraron características operativas deseables para el diseño de optimización de dosis-esquema.
  • El enfoque informa eficazmente la optimización de dosis-esquema adaptada a subgrupos de biomarcadores.

Conclusiones:

  • Una estrategia novedosa de optimización de dosis-esquema mejora el diseño de ensayos clínicos de inmunoterapia.
  • La adaptación del tratamiento basada en subgrupos de biomarcadores y el modelado integrado de resultados mejoran la evaluación de riesgos-beneficios.
  • Los métodos propuestos son adecuados para ensayos de fase temprana con tamaños de muestra limitados.